Correvio International is a privately held pharmaceutical company located in Geneva, Switzerland. Correvio LLC, our global supply chain operation, is located in Chester, Pennsylvania, USA. Currently, we commercialise AggrastatÂ® (tirofiban HCl)* in more than 50 countries worldwide either directly (Europe) or via our distributor and partner network.
We strive to help healthcare professionals improve outcomes for critically ill patients, currently in the field of Acute Coronary Syndromes (ACS). Our dedicated teams of employees offer considerable knowledge and experience and a shared goal of finding the right therapy for the right patient.
AggrastatÂ® is a reversible GP IIb/IIIa inhibitor for use in indicated Acute Coronary Syndrome patients. AggrastatÂ® is used to treat more than 250,000 patients annually and Correvio measures its business success in terms of Major Adverse Cardiac Events (MACE) prevented (approximately 18,000 MACE annually).1
Core to our business is our multi-lingual 24/7/365 Medical Information Center and our contemporary medical education tools and services.
High-risk ACS patients present an urgent medical challenge for healthcare professionals in their quest to prevent Myocardial Infarction (MI) and preserve patient quality of life. Approximately 1.4 million patients suffer from ACS/MI in Europe annually.
* AggrastatÂ® 50 microgram/ml solution for infusion.AggrastatÂ® 250 microgram/ml concentrate for solution for infusion.1. Correvio International SÃ rl data on file.
For more information on roles within this company please contact your Abbott Account Manager